ADVERTISEMENT

Buy Sun Pharma, Add Metropolis Lists HDFC Securities Among Others In Pharma, Healthcare; Q1 Results Preview

Overall, HDFC Securities expects strong performances from Lupin, Ipca, and Torrent, while Aurobindo, Zydus, and Max Healthcare may post muted results.

<div class="paragraphs"><p>IPM saw steady growth of 7.2% in Apr/May’25, led by steady 10% growth in the chronic segment, which was partly offset by ~6% growth in the acute segment for the same period.</p><p>(Sources:&nbsp;<a href="https://unsplash.com/@lunarts?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Volodymyr Hryshchenko</a>&nbsp;/&nbsp;<a href="https://unsplash.com/photos/person-holding-medicine-pills-aXbfOFQ_juU?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Unsplash</a>)</p></div>
IPM saw steady growth of 7.2% in Apr/May’25, led by steady 10% growth in the chronic segment, which was partly offset by ~6% growth in the acute segment for the same period.

(Sources: Volodymyr Hryshchenko / Unsplash)

Pharma coverage will see 11% YoY sales growth, driven by an 11% YoY increase in the India business along with 2% QoQ growth in US sales (+2% YoY). The hospital business is projected to grow by 15% YoY, as muted occupancy will be partly supported by steady average revenue per occupied beds, as well as M&As (Max Healthcare).
To continue reading this story
Subscribe to Unlock & Enjoy your 
Subscriber-Only
 benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit